Epigenetic change in kidney tumor: Downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Wang, Yong ^a,b   Zhang, Rui ^a   Wu, Donglu ^a   Lu, Zhihua ^a   Sun, Wentao ^a   Cai, Yong ^a   Wang, Chunxi ^a   Jin, Jingji ^a  

^a JILIN UNIVERSITY   (China)

^b Tumor Hospital of Jilin Province   (China)

Author keywords

Carbonate anhydrase IX; hMOF; Renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE MYST1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CLEAR CELL CARCINOMA; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; DOWN-REGULATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84873451028     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-8     Document Type: Article

References (32)

1. In and out: histone variant exchange in chromatin. Jin J, Cai Y, Li B, Conaway RC, Workman JL, Conaway JW, Kusch T, Trends Biochem Sci 2005 30 680 687 10.1016/j.tibs.2005.10.003 16257529 (Pubitemid 41668861)
2. The complex languige of chromatin regulation during transcription. Berger SL, Nature 2007 447 407 412 10.1038/nature05915 17522673 (Pubitemid 46816746)
3. Covalent modifications of histones during development and disease pathogenesis. Bhaumik SR, Smith E, Shilatifard A, Nat Struct Mol Biol 2007 14 1008 1016 10.1038/nsmb1337 17984963 (Pubitemid 350060343)
4. The divers functions of histone acetyltransferase complexes. Carrouzza MJ, Utley RT, Workman JL, Cote J, Trends Genet 2003 19 321 329 10.1016/S0168-9525(03)00115-X 12801725 (Pubitemid 36694615)
5. The mammalian ortholog of Drosophla MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Gupta A, Guerin-Peyrou TG, Sharma GG, Park C, Agarwal M, Ganju RK, Pandita S, Choi K, Sukumar S, Pandita RK, Ludwig T, Pandita TK, Mol Cell Biol 2008 28 397 409 10.1128/MCB.01045-07 17967868
6. MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Sharma GG, So S, Gupta A, Kumar R, Cayrou C, Avvakumov N, Bhadra U, Pandita RK, Porteus MH, Chen DJ, Cote J, Pandita TK, Mol Cell Biol 2010 30 3582 3595 10.1128/MCB.01476-09 20479123
7. Males absent on the first (MOF): from flies to humans. Rea S, Xouri G, Akhtar A, Oncogene 2007 26 5385 5394 10.1038/sj.onc.1210607 17694080 (Pubitemid 47255921)
8. A human protein complex homologus to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Smith ER, Cayrou C, Huang R, Lane WS, Côtê J, Lucchesi JC, Mol Cell Biol 2005 25 9175 9188 10.1128/MCB.25.21.9175-9188.2005 16227571 (Pubitemid 41507821)
9. Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mendjan S, Taipale M, Kind J, Holz H, Gebhardt P, Schelder M, Vermeulen M, Buscaino A, Duncan K, Mueller J, Wilm M, Stunnenberg HG, Saumweber H, Akhtar A, Mol Cell 2006 21 811 823 10.1016/j.molcel.2006.02.007 16543150 (Pubitemid 43376131)
10. Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. Cai Y, Jin J, Swanson SK, Cole MD, Choi SH, Florens L, Washburn MP, Conaway JW, Conaway RC, J Biol Chem 2010 285 4268 4272 10.1074/jbc.C109.087981 20018852
11. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB, Mol Cell 2006 24 841 851 10.1016/j.molcel.2006.11.026 17189187 (Pubitemid 44960096)
12. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Taiple M, Rea S, Richter K, Vilar A, Lichter P, Imhof A, Akhtar A, Mol Cell Biol 2005 25 6798 6810 10.1128/MCB.25.15.6798-6810. 2005 16024812 (Pubitemid 41023250)
13. A SIRT-LSD1 Co-repressor complex regulates notch target gene expression and development. Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Näär AM, Mol Cell 2011 42 689 699 10.1016/j.molcel.2011.04.020 21596603
14. The ATAC acetyl transferase complex controls mitotic progression by targeting non-histone substrates. Orpinell M, Fournier M, Riss A, Nagy Z, Krebs AR, Frontini M, Tora L, EMBO J 2010 29 2381 2394 10.1038/emboj.2010.125 20562830
15. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A, Lichter P, Int J Cancer 2008 122 1207 1213 18058815 (Pubitemid 351287218)
16. Globle histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Elsheikh S, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM, Ellis IO, Cancer Res 2009 69 3802 3809 10.1158/0008-5472.CAN-08-3907 19366799
17. Cancer stastistics. Jemal A, Siegel E, Ward E, Murray T, Xu J, Thun MJ, CA Cancer J Clin 2007 57 43 66 10.3322/canjclin.57.1.43 17237035
18. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recruitment disease. Janzen NK, Kim HL, Figlin RA, Belldegrun AS, Urol Clin North Am 2003 30 843 852 10.1016/S0094-0143(03) 00056-9 14680319 (Pubitemid 37485197)
19. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eichelberg C, Junker K, Ljungberg B, Moch H, Eur Urol 2009 55 851 863 10.1016/j.eururo.2009.01.003 19155123
20. Renal cell carcinoma: prognostic factors and patient selection. Belldegrun AS, Eur Urol Suppl 2007 6 477 483 10.1016/j.eursup.2007.01.016 (Pubitemid 46216190)
21. High expression of p53-induced ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma. Wu XR, Sha JJ, Liu DM, Chen YH, Yang GL, Zhang J, Xhen YY, Bo JJ, Huang YR, Eur J Sur Oncol 2012 39 100 106
22. Globle histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Mosashvilli D, Kahl P, Mertens C, Holzapfel S, Rogenhofer S, Hauser S, Büttner R, Von Ruecker A, Müller SC, Ellinger J, Cancer Sci 2010 101 2664 2669 10.1111/j.1349-7006.2010.01717.x 20825416
23. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, AJCC Cancer Staging Manual Chicago, IL: Springer 7 2010
24. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Choschzick M, Oosterwijl R, Muller V, Woelber L, Simon R, Moch H, Tennstedt P, Virchows Arch 2011 459 193 200 10.1007/s00428-011-1105-y 21691815
25. Carbonate anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Tostain J, Li G, Gentil-Perret A, Gigante M, Eur J Cancer 2010 46 3141 3148 10.1016/j.ejca.2010.07.020 20709527
26. The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Song JS, Chun SM, Lee JY, Kim DK, Kim YH, Jang SJ, Korean J Pathol 2011 45 386 396 10.4132/KoreanJPathol.2011.45.4.386
27. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, daignosis, and therapy. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E, Eur Urol 2010 58 75 83 10.1016/j.eururo.2010.03.015 20359812
28. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH, Br J Cancer 2007 96 104 109 10.1038/sj.bjc.6603530 17213826 (Pubitemid 46094646)
29. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ, Cancer 2009 115 1448 1458 10.1002/cncr.24163 19195047
30. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Harris AL, O'Byrne KJ, J Clin Oncol 2003 21 473 482 10.1200/JCO.2003.11.132 12560438 (Pubitemid 46613490)
31. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED, J Clin Oncol 2007 25 4757 4764 10.1200/JCO.2007.12.1087 17947723 (Pubitemid 350086478)
32. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ, Cancer Res 1997 57 2827 2831 9230182 (Pubitemid 27315020)